We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
-17.28%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$222M
AUM Growth
-$86.4M
Cap. Flow
-$22.6M
Cap. Flow %
-10.18%
Top 10 Hldgs %
33.77%
Holding
109
New
40
Increased
8
Reduced
21
Closed
35

Top Buys

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$11.9M
2
AMGN icon
Amgen
AMGN
+$7.88M
3
GILD icon
Gilead Sciences
GILD
+$7.77M
4
CELG
Celgene Corp
CELG
+$7.45M
5
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$6.84M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$12.1M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$10M
3
ENDP
Endo International plc
ENDP
+$9.56M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$9.04M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.41M

Sector Composition

Rank Sector Weight
1 Healthcare 82.57%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNCA
51
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.51M 0.68%
27,500
-6,250
-19% -$620K
DSCI
52
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$1.41M 0.64%
+300,000
New +$1.94M
ACHC icon
53
Acadia Healthcare
ACHC
$3.09B
$1.32M 0.6%
+40,000
New +$3.08M
RGNX icon
54
Regenxbio
RGNX
$579M
$1.32M 0.6%
+60,000
New +$1.53M
CHMA
55
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.29M 0.58%
+65,000
New +$1.61M
CORI
56
DELISTED
Corium International, Inc.
CORI
$1.17M 0.53%
+125,000
New +$1.5M
FOMX
57
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.1M 0.5%
150,000
-100,000
-40% -$1.02M
PTLA
58
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.07M 0.48%
25,000
-145,000
-85% -$7M
CPRX
59
DELISTED
Catalyst Pharmaceutical
CPRX
$1.05M 0.47%
+350,000
New +$1.51M
VCYT icon
60
Veracyte
VCYT
$4.73B
$951K 0.43%
202,800
+124,414
+159% +$1.18M
CBAY
61
DELISTED
Cymabay Therapeutics
CBAY
$776K 0.35%
+400,000
New +$1.09M
BDSI
62
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$590K 0.27%
106,200
– –
BDSI
63
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$556K 0.25%
100,000
-200,000
-67% -$1.48M
PBYI icon
64
Puma Biotechnology
PBYI
$428M
$490K 0.22%
6,500
-11,000
-63% -$1.04M
AKTX
65
Akari Therapeutics
AKTX
$20.1M
$488K 0.22%
+25
New +$296K
FATE icon
66
Fate Therapeutics
FATE
$318M
$476K 0.21%
+89,231
New +$609K
ONCE
67
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$417K 0.19%
+10,000
New +$522K
ZSAN
68
DELISTED
Zosano Pharma Corporation
ZSAN
$396K 0.18%
+143
New +$802K
OCRX
69
DELISTED
Ocera Therapeutics, Inc.
OCRX
$395K 0.18%
125,000
– –
UNIS
70
DELISTED
Unilife Corporation
UNIS
$343K 0.15%
35,000
-10,000
-22% -$149K
SRPT icon
71
Sarepta Therapeutics
SRPT
$1.82B
$321K 0.14%
+10,000
New +$339K
RPTP
72
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$303K 0.14%
+50,000
New +$613K
BIOL
73
DELISTED
Biolase, Inc.
BIOL
$270K 0.12%
24
– –
VIRX
74
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$237K 0.11%
1,395
-4,557
-77% -$1.64M
ADAP
75
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-76,850
Closed -$1.41M
1 2
3
4 5

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2015 Portfolio in Review

As of Q3 2015, Ghost Tree Capital held 109 positions worth $222M, down 28% from $309M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ghost Tree Capital withdrew a net $22.6M in Q3 2015, closing 35 positions and reducing 21 holdings. Its most notable exit was Biogen, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier, followed by Financials.

Against the trend, Ghost Tree Capital opened a new position in MALLINCKRODT PUBLIC LIMITED COMPANY worth $7.67M.

  • Ghost Tree Capital's largest Q3 2015 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 120,000 shares worth $7.67M.
  • Ghost Tree Capital added most to ZELTIQ Aesthetics, Inc. in Q3 2015, an estimated $2.81M increase.
  • Ghost Tree Capital's biggest Q3 2015 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $7M.
  • Ghost Tree Capital fully exited Biogen in Q3 2015, selling an estimated $12.1M.
  • Ghost Tree Capital's ten largest holdings make up 34% of its $222M portfolio in Q3 2015.
  • Ghost Tree Capital opened 40 new positions and closed 35 in Q3 2015.
  • Ghost Tree Capital's portfolio value fell 28% quarter-over-quarter to $222M.

Based on Ghost Tree Capital's 13F filing for Q3 2015, filed 16 Nov 2015.